Pharmacoeconomic studies of novel antibacterial drugs active against multidrug resistant pathogens


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacterbaumannii, Pseudomonas aeruginosa, and some Enterobacter species) are a group of the most dangerous multiple antibacterial resistant infectious agents. The choice of effective antibiotic therapy becomes a difficult task for limited state budgets, whereas the discovery of new molecules that can act on resistant pathogens is extremely difficult and requires a lot of resources and time. Therefore, the role of pharmacoeconomic analysis in the rational use of antibacterial drugs is growing significantly in our time. The results of pharmacoeconomic studies of innovative antibacterial drugs are an important tool for determining the feasibility of introducing these drugs into routine clinical practice. The analysis of relevant publications has revealed that the experience of pharmacoeconomic studies of using antibacterial drugs is limited and unreasonably rarely used for economic evaluation of the feasibility for administering novel antibacterial drugs. This study makes it possible to evaluate the experience with pharmacoeconomically analyzing the novel antibacterial drugs that are active against multidrug-resistant pathogens and to identify opportunities for further pharmacoeconomic studies of novel antibacterial drugs.

全文:

受限制的访问

作者简介

Dariya Savintseva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: dariyasavintseva@gmail.com
postgraduate student of the Department of Clinical Pharmacology and Propaedeutics Moscow , Russian Federation

Igor Sychev

Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation; Clinical Hospital named after S.S. Yudin

Email: sychevigor@mail.ru
Associate Professor of the Department of Clinical Pharmacology and Therapy of Russian Medical Academy of Continuing Professional Education, Head of the Clinical Pharmacology Department of Clinical Hospital named after S.S. Yudin, PhD of Medical Sciences Moscow , Russian Federation

Natalia Lazareva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natalia.lazareva@gmail.com
Professor, Department of Clinical Pharmacology and Propaedeutics Moscow , Russian Federation

参考

  1. Santajit S., Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed. Res. Int. 2016. DOI: https://doi.org/10.1155/2016/2475067
  2. Verhoef T.I., Morris S. Cost-effectiveness and pricing of antibacterial drugs. Chem. Biol. Drug. Des. 2014; 85 (1): 4-13. doi: 10.1111/cbdd.12417
  3. Jack N. Pendleton, Sean P. Gorman & Brendan F. Gilmore. Clinical relevance of the ESKAPE pathogens. Expert Review of Anti-infective Therapy. 2013; 11 (3): 297-308. doi: 10.1586/eri.13.12.
  4. Santajit S., Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int. 2016. DOI: https://doi.org/10.1155/2016/2475067.
  5. The Pew Charitable Trusts. Antibiotics Currently in Global Clinical Development. [Electronic resource]. Access mode: https://www.pewtrusts.org/en (circulation date 25 April, 2019).
  6. Государственный Реестр лекарственных средств. [Электронное издание]. Режим доступа: http://www.grls.ros-minzdrav.ru/default.aspx (дата обращения 23 марта 2019 г.) [Gosudarstvennyi reestr lekarstvennykh sredstv. [Electronic resource]. Access mode: https://grls.rosminzdrav.ru/default.aspx (circulation date 23 March, 2019). (in Russian).]
  7. Научная электронная библиотека e-LIBRARY.RU. [Электронный ресурс]. Режим доступа: https://elibrary.ru/ querybox.asp?scope=newquery (дата обращения 10 августа 2019 г.) [Nauchnaya elektronnaya biblioteka e-LIBRARY.RU. [Electronic resource]. Access mode: https://elibrary.ru/querybox. asp?scope=newquery (circulation date 10 August, 2019) (in Russian).]
  8. PubMed. [Electronic resource]. Access mode: https:// www.ncbi.nlm.nih.gov/pubmed (circulation date 26 June, 2019).
  9. Серпик В.Г., Ягудина Р. И. Фармакоэкономическая оценка применения препарата «Далбаванцин (ксидалба)» в лечении инфекций кожи и мягких тканей в условиях стационара в Российской Федерации. Фармакоэкономика: Теория и практика. 2017; 5 (2).
  10. Зырянов С.К., Белоусов Д.Ю., Афанасьева Е.В. Сравнительный фармакоэкономический анализ цефтаролинафосамил при лечении осложненных инфекций кожи и мягких тканей. Качественная клиническая практика. 2015; 3: 43-59.
  11. Колбин А.С., Вилюм И.А., Проскурин М.А., Балыкина Ю.Е. Фармакоэкономический анализ применения телаванцина в терапии пациентов с осложненными инфекциями кожи и мягких тканей в условиях здравоохранения РФ. Фармакоэкономика: теория и практика. 2016; 4 (2): 75-81.
  12. Колбин А.С., Вилюм И.А., Проскурин М.А., Балыкина Ю.Е. Фармакоэкономический анализ применения телаванцина в терапии пациентов с нозокомиальной пневмонией в условиях здравоохранения РФ. Фармакоэкономика: теория и практика. 2016; 4 (2): 88-92.
  13. Browne C., Muszbek N., Chapman R., Marsh K., Gould I.M., Seaton R.A., Allen M. Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia -infective endocarditis treated with either daptomycin or vancomycin. Int. J. Antimicrob. Agents. 2016; 47 (5): 357-61. doi: 10.1016/j.ijantimicag.2016.02.006
  14. Wright B.M., Eiland E.H. 3rd. Retrospective analysis of clinical and cost outcomes associated with methicillin-resistant Staphylococcus aureus complicated skin and skin structure infections treated with daptomycin, vancomycin, or linezolid. J. Pathog. 2011; 2011: 347969. doi: 10.4061/2011/347969.
  15. Bhavnani S.M., Prakhya A., Hammel J.P. & Ambrose P.G. Cost-effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin. Infect. Dis. 2009; 49: 691-8. doi: 10.1086/604710.
  16. Kauf T.L., McKinnon P., Corey G.R. et al. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect. Dis. 2015; 15: 503. doi: 10.1186/s12879-015-1261-9.
  17. Bounthavong M., Zargarzadeh A., Hsu D.I., Vanness D.J. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011; 14: 631-9. doi: 10.1016/j.jval.2010.12.006.
  18. McComb M.N., Collins C.D. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia. Pharmacotherapy. 2014; 34: 537-44. doi: 10.1002/phar.1393
  19. Huang X.Y., Lodise T., Friedland D., Beresford E.J. The economic impact of adding ceftarolinefosamil to hospital formulary for community acquired bacterial pneumonia: a hospital budget impact analysis in the United States. Value in Health. 2012; 15: a238. DOI: https://doi.org/10.1016/j.jval.2012.03.1284
  20. Xingyue Huang, Eric Beresford, Thomas Lodise, H. David Friedland. Ceftarolinefosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective. American Journal of Health-System Pharmacy. 2013; 70 (12): 1057-64. DOI: https://doi. org/10.2146/ajhp120438
  21. Athanasakis K., Petrakis I., Ollandezos M. et al. Antibacterial treatment of meticillin-resistant Staphylococcus aureus complicated skin and soft tissue infections: a cost and budget impact analysis in Greek hospitals. Infect. Dis. Ther. Epub. 2014. doi: 10.1007/s40121-014-0044-8.
  22. Stephens JM, Gao X, Patel DA, Verheggen BG, Shelbaya A, Haider S. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of line-zolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013; 5: 447-57. doi: 10.2147/CEOR.S46991
  23. Laohavaleeson S., Barriere S.L., Nicolau D.P. et al. Cost effectiveness of telavancin vs. vancomycin for the treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008; 28: 1471-82. doi: 10.1592/phco.28.12.1471
  24. Prabhu V., Foo J., Ahir H. et al. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. J. Med. Econ. 2017; 20: 840
  25. doi: 10.1080/13696998.2017.1333960
  26. Kauf T.L., Prabhu V.S., Medic G. et al. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infect. Dis. 2017; 17: 314. doi: 10.1186/s12879-017-2408-7
  27. Neil J. Turco, Sandra L. Kane-Gill, Inmaculada Hernandez, Louise-Marie Oleksiuk, Frank D'Amico & Aaron J. Pickering. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. Expert Opinion on Pharmacotherapy, 2018; 19 (4): 319-25. doi: 10.1080/14656566.2018.1442439
  28. Chen G.J., Pan S.C., Foo J., Morel C., Chen W.T., Wang J.T. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: a cost-utility model focusing on gram-negative bacteria. J. Microbiol. Immunol. Infect. 2019; 52: 807-15. DOI: https:// doi.org/10.1016/j.jmii.2019.04.003
  29. Brunetti L., Poustchi S., Cunningham D., Toscani M., Nguyen J., Lim J. et al. Clinical and economic impact of empirical extended-infusion piperacillin-tazobactam in a community medical center. Ann. Pharmacother. 2015; 49: 754-60. doi: 10.1177/1060028015579427
  30. Paladino J.A., Gilliland-Johnson K.K., Adelman M.H., Cohn S.M. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominalinfections. Surg. Infect. (Larchmt.). 2008; 9: 325. doi: 10.1089/sur.2007.010
  31. Muszbek N., Chapman R., Browne C., Marsh K., Gould I.M., et al. Using daptomycin in hospitalised patients with cSSTI caused by Staphylococcus aureus has an impact on costs. Chemotherapy. 2013; 59: 427-34. doi: 10.1159/000363280
  32. Grant E.M., Kuti J.L., Nicolau D.P., Nightingale C., Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous -infusion piperacillin-tazobactam program in a large community teaching hospital, Pharmacotherapy. 2002; 22: 471-83. doi: 10.1592/phco.22.7.471.33665
  33. Barron J., Turner R., Jaeger M., Adamson W., Singer J. Comparing the use of intravenous antibiotics under the medical benefit with the use of oral antibiotics under the pharmacy benefit in treating skin and soft tissue infections. Manag Care. 2012;21 (9): 44-52.
  34. Grau S., Lozano V., Valladares A., Cavanillas R., Xie Y., Nocea G. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis. Applied Health Economics and Health Policy. 2015; 13: 369-79. PMID: 25761545. doi: 10.1007/s40258-015-0162-9
  35. Jansen J.P., Kumar R., Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health. 2009; 12 (2): 234-44. doi: 10.1111/j.1524-4733.2008.00439.x
  36. Jansen J.P., Kumar R., Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 2009; 27 (12): 1045-56. doi: 10.2165/11310080-000000000-00000
  37. Edwards S.J., Wordsworth S., Clarke M.J. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. Eur. J. Health. Econ. 2012; 13: 18192. doi: 10.1007/s10198-011-0296-0
  38. Carson J.G., Turpin R.S., Hu H. et al. Cost analysis of five antimicrobial regimens for the treatment of intra-abdominal infection. Surg. Infect. 2008; 9 (1): 15-21. doi: 10.1089/sur.2006.081
  39. Ягудина Р.И., Серпик В.Г., Крылов А.Б., Скулкова Р.С. Выбор технологии сравнения при проведении фармакоэкономического анализа инновационных лекарственных препаратов. Фармакоэкономика: теория и практика. 2017; 5 (4): 5-11.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2020
##common.cookie##